FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Cheminformatics analysis of indoleamine and tryptophan 2,3-dioxygenase inhibitors: A descriptor and fingerprint based machine learning approach to disclose selectivity measures. PMID 39094327 · Comput Biol Med · 2024-Sep The record is a cheminformatics and machine learning study for drug discovery, not a clinical trial report. It lacks all key eligibility criteria: it is not a randomized trial, does not report Phase II/III results, and has no time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient Enrollment per Month (Accrual) in Clinical Trials Leading to the FDA Approval of New Cancer Drugs. PMID 39085451 · Target Oncol · 2024-Sep The record is a retrospective analysis of factors associated with patient accrual across many cancer trials, not an original report of a single Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407. PMID 39060124 · Pancreatology · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. PMID 39059185 · Eur J Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomized prospective study comparing the effect of low-volume bowel preparations for colonoscopy preparation in China. PMID 39054602 · Scand J Gastroenterol · 2024-Sep 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial. PMID 39038482 · Lancet Gastroenterol Hepatol · 2024-Sep Eligibility requires a drug-containing intervention. This trial evaluates a non-drug screening procedure (flexible sigmoidoscopy). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC. PMID 39029295 · Eur J Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy. PMID 39013265 · Eur J Cancer · 2024-Sep The record is from a Phase III randomized trial with a drug intervention in oncology, but the abstract explicitly focuses on safety/tolerability (timing, duration, and resolution of adverse events). There is no mention of a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios as a primary or key secondary outcome. The deterministic review also flagged 'no_time_to_event_signal'. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas. PMID 39002347 · Eur J Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. PMID 38990433 · Adv Ther · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-term outcomes of laparoscopic versus open distal gastrectomy for patients with advanced gastric cancer in North China: a multicenter randomized controlled trial. PMID 38981881 · Surg Endosc · 2024-Sep 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The effect of exercise and educational programs for breast cancer patients on the development of breast cancer-related lymphoedema: secondary endpoint from a randomized controlled trial in the Setouchi Breast Project-10. PMID 38980571 · Breast Cancer · 2024-Sep The study is a secondary endpoint analysis of a randomized trial in oncology with a time-to-event endpoint, but it lacks a drug-containing intervention and does not explicitly establish Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| AI-based selection of individuals for supplemental MRI in population-based breast cancer screening: the randomized ScreenTrustMRI trial. PMID 38977914 · Nat Med · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. PMID 38969879 · Nat Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer. PMID 38960798 · Clin Colorectal Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated proton and carbon ion beam radiotherapy for sacrococcygeal chordoma (ISAC): An open label, randomized, stratified, phase II trial. PMID 38944346 · Radiother Oncol · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. PMID 38942995 · Nat Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis. PMID 38938115 · Clin Pharmacol Ther · 2024-Sep 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Living Well: Protocol for a web-based program to improve quality of life in rural and urban ovarian cancer survivors. PMID 38914309 · Contemp Clin Trials · 2024-Sep 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant pembrolizumab, dabrafenib and trametinib in BRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial. PMID 38907159 · Nat Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial. PMID 38906970 · Br J Cancer · 2024-Sep The study meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result. However, it is excluded because the primary efficacy endpoint is pathologic complete response, which is not a time-to-event endpoint. The study does not report or analyze any time-to-event outcomes such as OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curves or hazard ratios are provided. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Patient Experiences of Specialty Palliative Care in the Perioperative Period for Cancer Surgery. PMID 38906425 · J Pain Symptom Manage · 2024-Sep This is a qualitative interview study embedded within a randomized controlled trial, focusing on patient experiences of palliative care in the perioperative period. It is not a report of the trial's primary efficacy results. It lacks a drug intervention and a time-to-event efficacy endpoint (OS, PFS, etc.). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study. PMID 38888812 · Int J Hematol · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association of CTACK, IL-2, and IL-13 with increased risk of lung cancer: A Mendelian randomization study. PMID 38885591 · Cytokine · 2024-Sep The study is a Mendelian randomization analysis investigating genetic associations between inflammatory cytokines and lung cancer risk. It is not a randomized clinical trial, does not report on a drug intervention or a primary/key secondary time-to-event efficacy endpoint (like OS, PFS, DFS from a Kaplan-Meier analysis or HR from a trial), and does not present results from a Phase II/III or III/IIIb randomized drug trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. PMID 38884137 · Am J Hematol · 2024-Sep The study is an eligible Phase III randomized oncology trial with a drug intervention and reports original results, but its primary efficacy endpoint is transfusion independence (a binary response), which is not a time-to-event endpoint. There is no signal of a time-to-event analysis (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or hazard ratios for such endpoints) in the provided title, abstract, or metadata. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The number of mesogastria containing metastatic lymph nodes predicts gastric cancer prognosis. PMID 38879382 · Surgery · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| PIPAC in patients with peritoneal metastases from gastrointestinal tract (PIPOX01): An open label, non-comparative phase 1/2 dose escalation and expansion trial. PMID 38878757 · Eur J Surg Oncol · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis. PMID 38861192 · Gastric Cancer · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Brazil-TNT: A Randomized Phase 2 Trial of Neoadjuvant Chemoradiation Followed by FOLFIRINOX Versus Chemoradiation for Stage II/III Rectal Cancer. PMID 38851990 · Clin Colorectal Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial of Postoperative Radiation Therapy After Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2 Trial 01.09). PMID 38851639 · Ann Surg Oncol · 2024-Sep The study is an oncology randomized trial with a primary time-to-event endpoint (time to local relapse, reported with HR). However, the intervention is adjuvant radiation therapy, which is a non-drug intervention. The eligibility criteria require a drug-containing intervention, and this study does not meet that criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Hybrid Type III Effectiveness-Implementation Trial to Optimize Medication Safety With Oral Antitumor Therapy in Real-World: The AMBORA Competence and Consultation Center. PMID 38848539 · JCO Oncol Pract · 2024-Sep The study is a Phase III randomized trial in human oncology with a drug intervention, but its primary endpoints are implementation and safety outcomes, not a time-to-event efficacy endpoint as required. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201). PMID 38833114 · Int J Clin Oncol · 2024-Sep The study is a prospective, non-randomized controlled trial, not a randomized trial. The abstract explicitly states 'non-randomized controlled study' and 'self-selected treatment'. While it is a prospective controlled study with a drug intervention and a time-to-event efficacy endpoint (DFS, OS), it does not meet the core requirement of being a randomized trial. Additionally, the trial phase is not explicitly stated as Phase III or equivalent. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Effectiveness of Rituximab Biosimilar RTXM83: A Retrospective Extension Study in Brazilian Patients with Diffuse Large B-Cell Lymphoma. PMID 38829416 · Oncol Ther · 2024-Sep The record describes a long-term observational extension of a randomized trial, not the original formal-result report of a Phase III or equivalent definitive trial. The phase of the underlying pivotal trial is not explicitly confirmed in the text, and the study itself is not the primary source of the trial results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS. PMID 38807035 · J Manag Care Spec Pharm · 2024-Sep While the study is a randomized phase 3 trial in oncology with a drug intervention, it is not eligible because it does not report a time-to-event efficacy endpoint. The analysis is a health-economic/budget impact study, which is excluded per the criteria. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP. PMID 38802107 · Br J Haematol · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Nationally Automated Colonoscopy Performance Feedback Increases Polyp Detection: The NED APRIQOT Randomized Controlled Trial. PMID 38759827 · Clin Gastroenterol Hepatol · 2024-Sep The study is a randomized trial in a human oncology context (colorectal neoplasms) with primary results. However, it is excluded because it does not test a drug-containing intervention (the intervention is an automated performance feedback system) and it does not report a primary time-to-event efficacy endpoint (the primary outcome is a performance indicator, polyp detection). Phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of tislelizumab on health-related quality of life in patients with recurrent or metastatic nasopharyngeal cancer. PMID 38671587 · Head Neck · 2024-Sep This is a secondary, quality-of-life analysis of a randomized Phase III trial (RATIONALE-309). While it is an original result report of a human malignant-neoplasm trial with a drug-containing intervention, it does not meet the cohort's inclusion criteria because the primary/key secondary endpoint is not a time-to-event efficacy measure (e.g., OS, PFS, DFS, etc.), but rather patient-reported outcomes on quality-of-life scales. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cancer patients have a reduced likelihood of dying in hospital with advance care planning in primary health care and a summarizing palliative plan: a prospective controlled non-randomized intervention trial. PMID 38662520 · Scand J Prim Health Care · 2024-Sep The study is a non-randomized intervention trial, not a randomized Phase III/IIIb or Phase II/III trial. It evaluates an advance care planning intervention (non-drug) with a primary outcome of place of death, not a time-to-event efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis. PMID 38627914 · Clin Pharmacol Ther · 2024-Sep The study is a model-based analysis predicting Phase 3 success probability for ritlecitinib in ulcerative colitis, not an oncology trial. It does not report original results of a completed randomized trial with a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Swiss trial of decompressive craniectomy versus best medical treatment of spontaneous supratentorial intracerebral haemorrhage (SWITCH): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial. PMID 38347736 · Eur Stroke J · 2024-Sep This is a clinical trial protocol for a non-oncology condition (spontaneous intracerebral hemorrhage) investigating a surgical intervention (decompressive craniectomy) versus best medical treatment. The primary outcome is a composite of death or dependence at 6 months (modified Rankin scale), not a time-to-event endpoint like OS, PFS, DFS, etc. It lacks Kaplan-Meier curves, hazard ratios, or other time-to-event analysis signals. It is also a protocol without reported results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Systemic therapies for advanced thyroid cancer - an update]. PMID 38346701 · Laryngorhinootologie · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical trial on the use of IMAGE1 S LIGHT (SPIES) vs. white light in the prevention of recurrence during transurethral resection of bladder tumors: Analysis after 12-month follow-up. PMID 38159804 · Actas Urol Esp (Engl Ed) · 2024-Sep The study is an oncology randomized trial with a time-to-event endpoint (RFS) and is an original report, but it does not meet the core requirement of a drug-containing intervention. The intervention is a surgical imaging technology (IMAGE1 S LIGHT vs. white light), not a pharmaceutical agent. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A 3-arm randomized control trial to compare the efficacy of re-circulant hyperthermic intravesical chemotherapy versus conventional intravesical mitomycin C and BCG therapy for intermediate-risk non-muscle invasive bladder cancer. PMID 39480527 · World J Urol · 2024-Oct-31 The record describes a randomized trial with a drug-containing intervention and a time-to-event efficacy endpoint (time to recurrence). However, the publication metadata and abstract do not explicitly state the trial phase (Phase III/IIIb or Phase II/III). Without this information, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of artificial liver support system treatment for immune checkpoint inhibitors related liver failure in patients with hepatocellular carcinoma: Protocol for a randomized controlled clinical trial. PMID 39640621 · Heliyon · 2024-Oct-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effects of the superior mesenteric artery approach versus the no-touch approach during pancreatoduodenectomy on the mobilization of circulating tumour cells and clusters in pancreatic cancer (CETUPANC): randomized clinical trial. PMID 39485887 · BJS Open · 2024-Oct-29 The trial is randomized and reports time-to-event efficacy endpoints, but it does not meet the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial, and the intervention is a surgical technique, not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer. PMID 39472345 · World J Urol · 2024-Oct-29 The record describes a subgroup analysis of a randomized trial comparing ADT regimens. While it is oncologic, human, randomized, and reports time-to-event efficacy endpoints, it is not the primary report of the trial's main results. The phase of the underlying trial (KYUCOG-1401) is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata, and the report type is secondary. Therefore, eligibility cannot be fully established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer. PMID 39494102 · World J Gastroenterol · 2024-Oct-28 The study is a randomized trial with a drug intervention and reports time-to-event efficacy endpoints. However, the abstract does not explicitly state the trial phase (e.g., Phase III, Phase IIIb, or Phase II/III). The deterministic review flagged 'phase3_evidence_unclear'. Since the phase is not explicitly confirmed in the provided metadata, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A Randomized Controlled Trial Assessing the Release of Circulating Tumor and Mesenchymal Cells in No-Touch Radical Nephrectomy. PMID 39518041 · Cancers (Basel) · 2024-Oct-25 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors. PMID 39448911 · BMC Cancer · 2024-Oct-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Investigating the effect of synbiotic supplementation on inflammatory indices in critically ill septic children: a protocol study for randomized control trial. PMID 39443948 · Trials · 2024-Oct-24 The record is a protocol for a randomized trial in pediatric sepsis, which is not a malignant neoplasm. It does not report or describe a time-to-event efficacy endpoint. The intervention is a synbiotic supplement, not a drug. It is not an original result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |